14-day Premium Trial Subscription Sign Up For FreeGet Free

Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

$208.56 (-0.35%)

Volume: 405k

Closed: Oct 15, 2021

Hollow Logo Score: 1.824

Alnylam Pharmaceuticals Stock Forecast

$208.56 (-0.35%)

Volume: 405k

Closed: Oct 15, 2021

Score Hollow Logo 1.824
Which way will ALNY go? Request
Stop-loss: $200.53 (-3.85%)
Earnings Date: Nov 03, 2021
Key Stats
P/E Ratio -27.95
Beta 0.95
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 64 and the stock is currently not being overbought or oversold

Weaker technical forecast for Alnylam Pharmaceuticals as stock downgraded to Buy Candidate.
(Updated on Oct 15, 2021)


Buy candidate since 2021-10-04 Gain 6.94%

The Alnylam Pharmaceuticals stock price fell by -0.35% on the last day (Friday, 15th Oct 2021) from $209.29 to $208.56. During the day the stock fluctuated 1.36% from a day low at $207.37 to a day high of $210.19. The price has risen in 8 of the last 10 days and is up by 8.24% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -50 thousand shares and in total, 405 thousand shares were bought and sold for approximately $84.43 million.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 6.77% during the next 3 months and, with a 90% probability hold a price between $192.06 and $232.62 at the end of this 3-month period.

Signals & Forecast

The Alnylam Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $205.19 and $193.82. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, October 14, 2021, and so far it has fallen -0.35%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss

Alnylam Pharmaceuticals finds support from accumulated volume at $200.25 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $2.82 between high and low, or 1.36%. For the last week, the stock has had a daily average volatility of 2.24%.

Our recommended stop-loss: $200.53 (-3.85%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 1 days ago.)

Is Alnylam Pharmaceuticals stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Alnylam Pharmaceuticals stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.

Current score: 1.824

Predicted Opening Price for Alnylam Pharmaceuticals of Monday, October 18, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price October 18, 2021 Current price
$208.71 $208.56 (Undervalued)
Buy Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 12, 2021 "Morgan Stanley" gave "$234.00 - $242.00" rating for ALNY. The price target was set to $204.53+0.4%.

Volatility and Risk
Daily Average Volatility: 2.24 %
Overall Risk: Very High High Medium Low Very Low
Volatility
2.24 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $209.29
Price: $208.56
Support: $200.25

ALNY Insider Trading Show all Trades

INSIDER POWER

1.510

Last 100 transactions
Buy: 499 855 | Sell: 330 974 (Shares)
Date Action Amount Person Type
Aug 09, 2021 Buy 10 834 Vaishnaw Akshay Common Stock
Aug 09, 2021 Sell 10 834 Vaishnaw Akshay Common Stock
Aug 09, 2021 Sell 10 834 Vaishnaw Akshay Performance Stock Option 2013 (right to buy)
Aug 06, 2021 Buy 28 064 Greenstreet Yvonne Common Stock
Aug 06, 2021 Buy 25 000 Greenstreet Yvonne Common Stock
Show all Insider Trades
INSIDER POWER

1.510

Last 100 transactions
Buy: 499 855 | Sell: 330 974 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 211.53 1.42 %
210.45 0.91 %
209.78 0.59 %
Current price: 208.56
Support 207.63 -0.45 %
206.96 -0.77 %
205.89 -1.28 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0 .
0 .
209.29 0.35 %
Current price 208.56
Support 200.25 -3.98%
183.17 -12.17%
177.08 -15.09%

Click to get the best stock tips daily for free!

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT